AB
CERE

Amalgamated Bank’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Amalgamated Bank’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-4,770
Closed -$195K – 3018
2024
Q2 		$195K Buy
4,770
+2,385
+100% +$99.3K ﹤0.01% 1585
2024
Q1 		$101K Sell
2,385
-7,642
-76% -$321K ﹤0.01% 1720
2023
Q4 		$425K Buy
10,027
+809
+9% +$23.2K ﹤0.01% 1503
2023
Q3 		$201K Hold
9,218
– – ﹤0.01% 1789
2023
Q2 		$293K Buy
9,218
+1,122
+14% +$34.4K ﹤0.01% 1679
2023
Q1 		$197K Sell
8,096
-1,462
-15% -$42.9K ﹤0.01% 1811
2022
Q4 		$301K Buy
9,558
+834
+10% +$23.5K ﹤0.01% 1696
2022
Q3 		$247K Buy
8,724
+138
+2% +$4.11K ﹤0.01% 1779
2022
Q2 		$227K Buy
8,586
+1,953
+29% +$55.5K ﹤0.01% 1822
2022
Q1 		$232K Sell
6,633
-497
-7% -$14.5K ﹤0.01% 1886
2021
Q4 		$231K Buy
7,130
+11
+0.2% +$388 ﹤0.01% 1929
2021
Q3 		$210K Buy
+7,119
New +$200K ﹤0.01% 1979

Other funds holding CERE

IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

Amalgamated Bank's CERE Position: Q3 2024 in Review

Amalgamated Bank sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 4,770 shares — an estimated $195K sold.

Amalgamated Bank first reported a position in CERE in Q3 2021 and held it in 12 quarters. The position peaked at $425K in Q4 2023. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

  • Amalgamated Bank reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • Amalgamated Bank sold 4,770 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $195K.
  • Amalgamated Bank first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q3 2021 and held it in 12 quarters.
  • Amalgamated Bank's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $425K in Q4 2023.
  • 2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on Amalgamated Bank's 13F filing for Q3 2024, filed 30 Oct 2024.